Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Duality Advisers LP

Duality Advisers LP lowered its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 23.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,148 shares of the company’s stock after selling 28,723 shares during the quarter. Duality Advisers LP owned 0.07% of Vir Biotechnology worth $957,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Signaturefd LLC lifted its holdings in Vir Biotechnology by 258.5% in the fourth quarter. Signaturefd LLC now owns 3,327 shares of the company’s stock worth $33,000 after acquiring an additional 2,399 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Vir Biotechnology by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,448 shares of the company’s stock worth $32,000 after purchasing an additional 1,692 shares during the period. Fifth Third Bancorp lifted its holdings in shares of Vir Biotechnology by 69.3% in the 3rd quarter. Fifth Third Bancorp now owns 3,941 shares of the company’s stock worth $37,000 after purchasing an additional 1,613 shares during the last quarter. Federated Hermes Inc. acquired a new position in Vir Biotechnology during the 4th quarter valued at approximately $69,000. Finally, CWM LLC grew its stake in Vir Biotechnology by 882.7% during the 3rd quarter. CWM LLC now owns 7,488 shares of the company’s stock worth $70,000 after buying an additional 6,726 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Vir Biotechnology from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Friday, February 23rd. HC Wainwright reissued a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, March 15th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.38.

Vir Biotechnology Stock Up 0.4 %

Shares of VIR stock opened at $8.13 on Wednesday. The stock has a 50-day simple moving average of $10.07 and a 200 day simple moving average of $9.61. Vir Biotechnology, Inc. has a fifty-two week low of $7.72 and a fifty-two week high of $27.48.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.28. The company had revenue of $16.80 million for the quarter, compared to analysts’ expectations of $11.18 million. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The business’s revenue was down 66.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.76) EPS. On average, equities research analysts anticipate that Vir Biotechnology, Inc. will post -4.04 EPS for the current year.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, CEO Backer Marianne De sold 72,995 shares of the business’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total value of $690,532.70. Following the transaction, the chief executive officer now owns 678,457 shares in the company, valued at $6,418,203.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Vir Biotechnology news, CEO Backer Marianne De sold 72,995 shares of the stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $9.46, for a total transaction of $690,532.70. Following the transaction, the chief executive officer now directly owns 678,457 shares of the company’s stock, valued at $6,418,203.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Ann M. Hanly sold 2,711 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $10.05, for a total value of $27,245.55. Following the completion of the sale, the executive vice president now directly owns 132,069 shares of the company’s stock, valued at approximately $1,327,293.45. The disclosure for this sale can be found here. Insiders sold a total of 152,831 shares of company stock valued at $1,525,844 in the last three months. 18.10% of the stock is currently owned by corporate insiders.

Vir Biotechnology Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.